Loading...
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
AIMS: Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR‐CM) in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT). While ATTR‐ACT was not designed for a dose‐specific assessment, further analysis from ATTR‐ACT and its long‐term extension study (L...
Na minha lista:
| Udgivet i: | Eur J Heart Fail |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons, Ltd
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8048553/ https://ncbi.nlm.nih.gov/pubmed/33070419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.2027 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|